The Discovery to Market project is an important part of the innovative Global MBA curriculum.

In this course, students learn to assess the commercial potential of scientific discoveries and technological innovations, with the goal of producing future Chief Innovation Officers and informed CEOs who truly understand the complex interplay of science, technology and innovation to create revolutionary business models for companies around the world.

 

How D2M is unique:

  • Focus on commercialization and entrepreneurship as a means to meet societal needs; i.e. by creating a successful business model a technology can be brought to market for medical, scientific and humanitarian purposes.
  • The core philosophy of D2M is experiential learning.
  • Learn critical aspects of science, in addition to the fundamentals of the technology commercialization process,.
  • Students have diverse cultural, professional and business backgrounds. There are no science, medical or engineering prerequisites. D2M is part of a general MBA programs.
  • Student teams are business students only; responsibility for understanding the invention and its commercial feasibility falls squarely on the shoulders of business students.
  • Working in teams, students will determine the feasibility of commercializing real scientific inventions such as biomarkers, medical devices, pharmaceuticals and biologics, and health IT.
  • Industry experts in entrepreneurship, law and regulation, technology, strategy, science, and medicine advise student teams.
  • Work on real inventions through our working agreements with project partners.

The Johns Hopkins Carey Business School works closely with the Johns Hopkins University School of Medicine (JHUSOM), School of Biomedical Engineering (BME) and the Center for Bioengineering Innovation and Design (CBID), the office of Johns Hopkins Technology Transfer (JHTT), the US Army Medical Research and Material Command Telemedicine & Advanced Technology Research Center (TATRC), and National Institute of Health (NIH).